Oncology

ImCheck's ICT01 gains an orphan drug designation from the FDA, offering hope for acute myeloid leukemia (AML) treatment in older patients with limited options.

The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.

The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing options, and streamlined Risk Evaluation and Mitigation Strategy program.

NCCN updates ovarian cancer guidelines, emphasizing personalized maintenance therapy with niraparib for HR-deficient patients, enhancing oncology pharmacists' roles.

Enzalutamide combined with leuprolide significantly enhances survival in high-risk non-metastatic prostate cancer, marking a breakthrough in treatment strategies.

Research reveals HER2-negative breast cancer shows higher pCR rates than HER2-low, influencing neoadjuvant chemotherapy strategies for early-stage patients.

Research reveals that higher BMI in women with cardiovascular disease significantly increases breast cancer risk, highlighting the need for targeted prevention strategies.

An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for zanubrutinib.

The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.

The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.

Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.

Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.

FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care.

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

The long-term outcomes from the CARTITUDE-1 trial in multiple myeloma and durable complete response data from the STARGLO trial in diffuse large B-cell lymphoma can be significant for these disease states.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses the value of the 2025 ATOPP Summit in advancing oncology pharmacy through collaboration, innovation, and actionable strategies aligned with evolving value-based care models.

Obesity and high-fat diets enhance the aggressiveness of triple-negative breast cancer through exosome-mediated mechanisms, revealing new therapeutic targets.

Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy.

New data reveal isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.

Research reveals that combining radiotherapy or immune-modulating drugs with CDK4/6 inhibitors enhances treatment efficacy in HR+/HER2– breast cancer.

Y-90 resin microspheres offer a new option for patients with liver cancer for the treatment of unresectable hepatocellular carcinoma.

Serena Mitaly, PharmD, outlines how Ochsner Health is building a sustainable pharmacogenomics program by integrating clinical decision support tools into the EMR, educating providers, addressing reimbursement barriers, and expanding the role of PGx pharmacists in personalized medicine.

Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Andrew E. Esch, MD, MBA, discusses the need for systemic reforms to support pharmacist-led medication optimization in palliative and community-based care.